• Services
    • Overview
    • Autoantibody Biomarker Profiling
    • Oncology Drug Screening
    • Systems Serology
    • Vaccine Development
    • Custom Protein Arrays
  • Applications
        • Disease Area
          • Autoimmune Disease
          • Immuno-oncology
          • Neurological Disease
          • Infectious Disease
        • Application Area
          • Biomarker Discovery
          • Patient Stratification
          • Response & Adverse Event Prediction
          • Diagnostics & CDx Development
  • Technology
    • Overview
    • KREX Protein Folding Technology
    • ORVAR Autoantigen Discovery Platform
    • The Value of Autoantibodies
    • Bioinformatics for Autoantibodies
  • Resources
    • Videos
    • Publications
    • Product Information
    • White Papers & Case Studies
    • Protein List
    • FAQ
  • About
    • Company Overview
      • Patents
    • Meet Our Team
    • News & Events
  • Menu Menu
  • Join Our Team
  • Contact

News & Events

Keep up to date on Sengenics news and events

Events

Sengenics is sponsoring ELRIG’s Research & Innovation 2022. Visit us at booth #14.

March 29 & 30, 2022
The Kings Centre, Oxford UK
Learn More →
Press Releases

Sengenics Strengthens Strategy to Enable Wider Access to Patented Protein Microarray Technology with the Launch of the Sengenics i-Ome® Protein Array Kit

March 8, 2022
Learn More →
Press Releases

Sengenics Continues to Expand Global Footprint with New Distribution Agreements in the Asia-Pacific Region

December 7, 2021
Learn More →
Press Releases

Sengenics Bolsters Leadership Team with Two New Appointments

May 4, 2021
Learn More →
Press Releases

Sengenics Launches AxCESS, a Research Services Suite to Enable Wider Accessibility to Protein Arrays Developed Using its Patented KREX Protein Folding Technology

March 8, 2021
Learn More →
Press Releases

Sengenics Awarded Prestigious Michael J. Fox Foundation Grant to Determine the Role of Autoantibodies in the Progression of Parkinson’s

December 15, 2020
Learn More →
Press Releases

Sengenics Launches SEROMAX, an At-Home, Antibody Sample Collection Kit That Will Revolutionise Patient Recruitment and Monitoring in Clinical Trials

October 29, 2020
Learn More →
Press Releases

Summa Equity Acquires Sengenics to Advance Precision Medicine through Proteomics

October 14, 2020
Learn More →
Press Releases

Sengenics Launches ImmuSAFE COVID+, the World’s First High-Throughput, Multi-Antigen COVID-19 Biochip Test

June 23, 2020
Learn More →
  • ‹
  • 1
  • 2
  • 3
  • 4
  • ›
Loading...

  • Services
  • Applications
  • Technology
  • Resources
  • About

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.

Copyright 2008 – 2022 Sengenics All rights reserved. Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D

Terms & Conditions | Terms of Use | Privacy Statement | Cookie Policy | Code of Conduct | Whistleblowing Policy

Design and development by RainCastle Communications.

This site uses cookies. By continuing to use this site, you accept our use of cookies. Learn more about our Privacy Statement and Cookie Policy here.

I Accept

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only

"*" indicates required fields

Watch the video

"*" Indicates required fields

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation


Read the Review

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Read the publication

"*" Indicates required fields

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Watch the video

"*" Indicates required fields

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Watch the video

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.